Eric Sachetta Acquires 27,304 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 27,304 shares of the stock in a transaction dated Monday, August 31st. The stock was bought at an average price of $3.54 per share, for a total transaction of $96,656.16. Following the purchase, the director directly owned 294,784 shares of the company’s stock, valued at approximately $1,043,535.36. The trade was a 10.21% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Eric Sachetta also recently made the following trade(s):

• On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $129,127.28.
• On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.18 per share, with a total value of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta purchased 9,708 shares of Sensus Healthcare stock. The stock was bought at an average cost of $3.29 per share, with a total value of $31,939.32.
• On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was bought at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Down 5.9%

Sensus Healthcare stock opened at $3.33 on Wednesday. The firm has a market cap of $54.82 million, a PE ratio of -3.54 and a beta of 1.10. Sensus Healthcare, Inc. has a 12 month low of $2.66 and a 12 month high of $5.49. The stock’s 50 day simple moving average is $3.08 and its two-hundred day simple moving average is $3.50.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Finally, Lake Street Capital cut their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensus Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $5.83.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SRTS. Greenline Wealth Management LLC purchased a new position in Sensus Healthcare in the 4th quarter valued at about $513,000. Rothschild Wealth LLC purchased a new stake in Sensus Healthcare during the 4th quarter worth approximately $500,000. North Star Investment Management Corp. purchased a new stake in Sensus Healthcare during the 1st quarter worth approximately $500,000. Pacific Ridge Capital Partners LLC raised its holdings in shares of Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after acquiring an additional 125,245 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Sensus Healthcare during the second quarter valued at approximately $303,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.